|From: hazeleye 476% (Rep: 224)||Date: 04/26/2012 09:57|
|Forum: Dyax - Msg #346||Thread #673393961 (Rec: 0) |
|Excellent quarterly report last night, very steady growth and very favorable language...|
my favorite quote:
"Looking to the future, we have focused our investments on label expansion strategies for KALBITOR and development of new diagnostic and therapeutic products that address a broader set of angioedemas and patient needs. Combined with the significant potential of our robust and maturing LFRP portfolio, these investments create multiple opportunities for significant and sustained value creation."
LFRP = Licensing and Funded Research Program
In just the past six weeks or so Dyax has added these new partners via their LFRP program and phage display technology: GE Healthcare and Eclipse Therapeutics
Plus don't forget their other partners: Eli Lilly, Amgen, Biogen, Genetech, Merrimack, Sanofi-Aventis, and others.
DYAX, best chart in over 5 years. Slow and steady climb up. It's going to be grand slam.
Been holding for a year now. No intentions of selling.
Share This Post:
The place to be for 2011+
TheLion.com | About Us | Agreement & Disclaimer | Privacy | Twitter
© 1999- TheLion.com, Inc.